Press Releases
Bayer Comments on Monsanto’s Statement Regarding Proposed Transaction
Bayer announced that it looks forward to engaging in constructive discussions with Monsanto regarding the proposed transaction. Bayer reiterated that its USD 122 per share...
Press Releases
Novo Nordisk IDegLira receives positive 16-0 vote in favour of approval from FDA
Novo Nordisk announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the US Food and Drug Administration (FDA) voted 16-0, recommending the approval...
Press Releases
Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%
Allergan plc announced that the New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescription product for the treatment of persistent...
Press Releases
Seqirus receives FDA approval for FLUCELVAX QUADRIVALENT
CSL announced that the US FDA has approved Seqirus’ FLUCELVAX QUADRIVALENT™ (Influenza Vaccine), the first four-strain, cell culture-derived, inactivated seasonal influenza vaccine for people aged...
Press Releases
Rituximab regulatory submission accepted by European Medicines
Sandoz advances biosimilar portfolio with sixth major biosimilar file acceptance in less than one year Sandoz is seeking approval for all indications included in...
Press Releases
FDA Expands Invokamet Label to Include First-Line Treatment of with type 2 diabetes
Janssen Pharmaceuticals, Inc announced the U.S. FDA has approved INVOKAMET®, a fixed-dose combination therapy of INVOKANA® (canagliflozin) and metformin hydrochloride, for first-line treatment of adults...
Press Releases
Anti-Cancer Agent vastin ,Obtained Approval for Additional Indication of Advanced or Recurrent Cervical Cancer
Chugai Pharmaceutical Co Ltd announced that it gained approval by the Japanese Ministry of Health, Labour and Welfare (MHLW) on May 23, 2016, for “advanced...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.